The FDA announced the approval of darolutamide for treating metastatic castration-sensitive prostate cancer. This review was conducted under Project Orbis, which allows for concurrent submission and review...
Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with opioid dependence, prostate cancer, and multiple sclerosis.
